DURHAM, N.C. -- (BUSINESS WIRE) -- Bioventus, a leader in active orthopaedic healing, today announced that it has entered into an agreement with Galderma to acquire the International assets for DUROLANE®, a product that helps relieve the pain of osteoarthritis (OA) in a variety of joints.* Bioventus previously had exclusive global distribution rights and served as the distributor for DUROLANE in Europe, Canada and Australia.
With the new agreement, Galderma will continue to serve as the manufacturer of DUROLANE; however, Bioventus now controls all future plans and distribution for the product outside of the United States. Financial terms of the agreement were not disclosed.
“DUROLANE has been an invaluable product to numerous OA sufferers throughout the world,” said Anthony Bihl, CEO of Bioventus. “We see growth potential and new market opportunities for the product, and determined that controlling the assets puts us in the best position to realize these opportunities.”
Treating patients for more than 12 years, DUROLANE is the original single-injection joint-fluid treatment and contains high levels of non-animal stabilized hyaluronic acid (NASHA®) technology. Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. It is injected into indicated joints* affected by mild to moderate OA to help relieve pain, restore lubrication and improve joint function. The product is available in two formats – DUROLANE (3ml) for mild to moderate knee or hip OA, and DUROLANE SJ (1ml) for indicated* smaller joints.
Bioventus is a biologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company’s innovative products include market-leading devices, therapies and diagnostics that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine, and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved for the symptomatic treatment associated with mild to moderate arthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes. DUROLANE is also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.
Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes. DUROLANE SJ is also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.
DUROLANE and NASHA are registered trademarks of Galderma S.A.